205 related articles for article (PubMed ID: 31549944)
21. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
Soyer P; Dohan A; Patkar D; Gottschalk A
J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI using MR fluoroscopic triggering and slow injection technique.
Goshima S; Kanematsu M; Kondo H; Watanabe H; Kawada H; Moriyama N; Bae KT
AJR Am J Roentgenol; 2013 Sep; 201(3):578-82. PubMed ID: 23971449
[TBL] [Abstract][Full Text] [Related]
23. Focal nodular hyperplasia: a weight-based, intraindividual comparison of gadobenate dimeglumine and gadoxetate disodium-enhanced MRI.
Taibbi A; Brancatelli G; Matranga D; Midiri M; Lagalla R; Bartolotta TV
Diagn Interv Radiol; 2019 Mar; 25(2):95-101. PubMed ID: 30860073
[TBL] [Abstract][Full Text] [Related]
24. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality.
Davenport MS; Viglianti BL; Al-Hawary MM; Caoili EM; Kaza RK; Liu PS; Maturen KE; Chenevert TL; Hussain HK
Radiology; 2013 Feb; 266(2):452-61. PubMed ID: 23192781
[TBL] [Abstract][Full Text] [Related]
25. Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses.
Kim SY; Park SH; Wu EH; Wang ZJ; Hope TA; Chang WC; Yeh BM
AJR Am J Roentgenol; 2015 Jun; 204(6):1220-7. PubMed ID: 26001231
[TBL] [Abstract][Full Text] [Related]
26. Respiratory motion in children and young adults undergoing liver magnetic resonance imaging with intravenous gadoxetate disodium contrast material.
Gilligan LA; Trout AT; Anton CG; Schapiro AH; Towbin AJ; Dillman JR
Pediatr Radiol; 2019 Aug; 49(9):1171-1176. PubMed ID: 31203405
[TBL] [Abstract][Full Text] [Related]
27. Incidence and severity of acute adverse reactions to four different gadolinium-based MR contrast agents.
Okigawa T; Utsunomiya D; Tajiri S; Okumura S; Sasao A; Wada H; Oda S; Arimura H; Hayashida E; Urata J; Yamashita Y
Magn Reson Med Sci; 2014; 13(1):1-6. PubMed ID: 24492735
[TBL] [Abstract][Full Text] [Related]
28. Comparison of enhancement of the vestibular perilymph between gadoterate meglumine and gadobutrol at 3-Tesla in Meniere's disease.
Eliezer M; Poillon G; Gillibert A; Horion J; Cruypeninck Y; Gerardin E; Magne N; Attyé A
Diagn Interv Imaging; 2018 May; 99(5):271-277. PubMed ID: 29398574
[TBL] [Abstract][Full Text] [Related]
29. Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30,000 MR examinations.
De Ridder F; De Maeseneer M; Stadnik T; Luypaert R; Osteaux M
JBR-BTR; 2001 Aug; 84(4):150-2. PubMed ID: 11688727
[TBL] [Abstract][Full Text] [Related]
30. Age, But Not Repeated Exposure to Gadoterate Meglumine, Is Associated With T1- and T2-Weighted Signal Intensity Changes in the Deep Brain Nuclei of Pediatric Patients.
Pozeg P; Forget J; Meuli RA; Maeder P
Invest Radiol; 2019 Sep; 54(9):537-548. PubMed ID: 30973458
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of incidence of acute transient dyspnea and related artifacts after administration of gadoxetate disodium: a prospective observational study.
Grazioli L; Faletti R; Frittoli B; Battisti G; Ambrosini R; Romanini L; Gatti M; Fonio P
Radiol Med; 2018 Dec; 123(12):910-917. PubMed ID: 30084108
[TBL] [Abstract][Full Text] [Related]
32. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
Liu BP; Rosenberg M; Saverio P; Weon YC; Peters S; Ardellier FD; Boeckenhoff A; Endrikat J
AJR Am J Roentgenol; 2021 Nov; 217(5):1195-1205. PubMed ID: 34133205
[No Abstract] [Full Text] [Related]
33. CAIPIRINHA-Dixon-TWIST (CDT)-VIBE MR imaging of the liver at 3.0T with gadoxetate disodium: a solution for transient arterial-phase respiratory motion-related artifacts?
Gruber L; Rainer V; Plaikner M; Kremser C; Jaschke W; Henninger B
Eur Radiol; 2018 May; 28(5):2013-2021. PubMed ID: 29264636
[TBL] [Abstract][Full Text] [Related]
34. Comparison of transient severe motion in gadoxetate disodium and gadopentetate dimeglumine-enhanced MRI: effect of modified breath-holding method.
Song JS; Choi EJ; Park EH; Lee JH
Eur Radiol; 2018 Mar; 28(3):1132-1139. PubMed ID: 28986630
[TBL] [Abstract][Full Text] [Related]
35. Transient Severe Respiratory Motion Artifacts After Application of Gadoxetate Disodium: What We Currently Know.
Well L; Weinrich JM; Adam G; Bannas P
Rofo; 2018 Jan; 190(1):20-30. PubMed ID: 29156475
[TBL] [Abstract][Full Text] [Related]
36. A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging With Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine.
Scali EP; Walshe T; Tiwari HA; Harris AC; Chang SD
Can Assoc Radiol J; 2017 Aug; 68(3):293-307. PubMed ID: 28583364
[TBL] [Abstract][Full Text] [Related]
37. Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone and soft-tissue disease.
Colafati GS; Rossi E; Carducci C; Piga S; Voicu IP; Mastronuzzi A; Tomà P
Pediatr Radiol; 2018 Nov; 48(12):1724-1735. PubMed ID: 30046901
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of 3.0-T MRI Brain Signal after Exposure to Gadoterate Meglumine in Women with High Breast Cancer Risk and Screening Breast MRI.
Bennani-Baiti B; Krug B; Giese D; Hellmich M; Bartsch S; Helbich TH; Baltzer PAT
Radiology; 2019 Dec; 293(3):523-530. PubMed ID: 31638488
[TBL] [Abstract][Full Text] [Related]
39. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
Aran S; Shaqdan KW; Abujudeh HH
Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
[TBL] [Abstract][Full Text] [Related]
40. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.
Scala M; Koob M; de Buttet S; Bourrinet P; Felices M; Jurkiewicz E
Invest Radiol; 2018 Feb; 53(2):70-79. PubMed ID: 28906338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
